drugset / Trial / NCT04495816

COVID-19 Anosmia Study

NCT04495816 ↗

Phase 2 Completed 139 enrolled Icahn School of Medicine at Mount Sinai
RandomizedParallel-groupDouble-blindTreatment

Summary

To capture the natural history of COVID-19 associated olfactory dysfunction as measured by two patient reported outcome measures (SNOT-22, QOD-NS) and a 6-week BSIT with a comparison to an intervention arm receiving daily omega-3 supplements.

Timeline

Start
2020-07-15
Primary completion
2021-12-31
Completion
2021-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Omega-3 Fatty Acid Supplement Unknown 1000 mg Oral

Indications